MedTrace Logo

Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

NCT01234129 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2010-11-04

No results posted yet for this study

Summary

Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.

Conditions

Interventions

DRUG

zoledronic acid

zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years

Sponsors & Collaborators

  • Instituto Mexicano del Seguro Social

    lead OTHER_GOV

Principal Investigators

  • Agustin Aviles, MD · Instituto Mexicano del Seguro Social

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01234129 on ClinicalTrials.gov